<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495533</url>
  </required_header>
  <id_info>
    <org_study_id>FIM-DCA-01</org_study_id>
    <nct_id>NCT01495533</nct_id>
  </id_info>
  <brief_title>Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter</brief_title>
  <official_title>Treatment of Coronary In-stent Restenosis by a Paclitaxel Coated AngioSculpt Scoring Balloon - a First-in-man Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the treatment of coronary Bare Metal Stent restenosis&#xD;
      with a drug coated AngioSculpt scoring balloon.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, controlled, multicenter, randomized, single-blind trial. The aim is to examine&#xD;
      the treatment of coronary Bare Metal Stent restenosis with a drug coated AngioSculpt scoring&#xD;
      balloon. Patients are randomized to treatment by an AngioSculpt scoring balloon (no drug&#xD;
      coating)or a drug coated AngioSculpt scoring balloon (paclitaxel 3.0 µg/mm²). Primary&#xD;
      efficacy endpoint is late lumen loss in-segment at 6 months. Key secondary endpoints include&#xD;
      procedural Success, MACE (cardiac death, target vessel myocardial infarction, and clinically&#xD;
      driven target lesion revascularization at 6 months). Individual clinical endpoints include&#xD;
      stent thrombosis (ARC), cardiac death, any death, target vessel myocardial infarction, any&#xD;
      infarction, clinically driven target lesion revascularization, clinically driven target&#xD;
      vessel revascularization, any revascularization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss in-segment</measure>
    <time_frame>6 months</time_frame>
    <description>angiographic late lumen loss in-segment assessed by quantitative coronary angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 days</time_frame>
    <description>&lt;50% final DS and the absence of in-hospital MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>6 months</time_frame>
    <description>the occurence of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization at 6 months (before planned control angiography)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>In-stent Arterial Restenosis</condition>
  <arm_group>
    <arm_group_label>uncoated AngioSculpt(R)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug coated AngioSculpt(R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated AngioSculpt(R)</intervention_name>
    <description>Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)</description>
    <arm_group_label>uncoated AngioSculpt(R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug coated AngioSculpt(R)</intervention_name>
    <description>Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)</description>
    <arm_group_label>drug coated AngioSculpt(R)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
          -  clinical evidence of stable or unstable angina or a positive functional study&#xD;
&#xD;
          -  patients with ≤ 2 primary in-stent restenosis (ISR) lesions (≥ 70% diameter stenosis)&#xD;
             within previously placed bare metal stents (BMS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute myocardial infarction within the past 72 hours&#xD;
&#xD;
          -  chronic renal insufficiency with serum creatinine levels &gt;2.0 mg per deciliter%&#xD;
&#xD;
          -  known hypersensitivity or contraindications to aspirin, heparin, clopidogrel,&#xD;
             ticlopidine or paclitaxel, and sensitivity to contrast media not amenable to&#xD;
             premedication&#xD;
&#xD;
          -  concomitant medical illness associated with a life-expectancy of less than two years&#xD;
&#xD;
          -  stented segment length ≥30 mm, vessel diameter &lt;2.5 mm, diameter stenosis &lt;70%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danta Pazzanese Heart Institute</name>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine III, UKS</name>
      <address>
        <city>Homburg Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2011</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

